Patient Information Leaflet
ATERINA 15 mg Soft Capsules
Sulodexide
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
1. What ATERINA capsules are and what they are used for
2. What you need to know before you start taking ATERINA capsules
3. How to take ATERINA capsules
4. Possible side effects
5. Storage of ATERINA capsules
6. Contents of the pack and additional information
ATERINA capsules contain sulodexide, which belongs to a group of medicines called antithrombotics, which are used to prevent and treat blood clots (thrombi) that may form in blood vessels.
ATERINA capsules is indicated in adults for:
Due to its antithrombotic effect, ATERINA capsules improves blood circulation and alleviates symptoms associated with chronic venous insufficiency.
-Treatment of chronic venous ulcer
-Treatment of symptoms of intermittent claudication in peripheral arterial occlusive disease (stage II).
Do not take ATERINA capsules
- if you are allergic to the active ingredient (sulodexide) or to any of the other components of this medication (listed in section 6), to heparin or heparinoids (blood-thinning medications),
- if you have a risk of bleeding or suffer from bleeding disorders.
Warnings and precautions
Consult your doctor or pharmacist before starting to take ATERINA capsules.
Children and adolescents
The safety and efficacy of ATERINA have not been established in children and adolescents under 18 years of age. No data are available.
Taking ATERINA capsules with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
ATERINA capsules may increase the anticoagulant effect of heparin-based medications and other oral anticoagulants if taken simultaneously (see Warnings and Precautions section).
Taking ATERINA capsules with food and drinks
No information is available on interactions with food or drinks.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
As a precaution, it is preferable to avoid the use of ATERINA capsules during pregnancy.
Breastfeeding
ATERINA capsules should not be taken during breastfeeding.
Fertility
Studies conducted in animals do not indicate direct or indirect harmful effects on the fertility of males and females.
Driving and operating machines
This medication does not affect or insignificantly affects the ability to drive and operate machines.
ATERINA capsules contain Yellow-orange S (E 110), Red Cochineal A (E 124), Sodium ethyl para-hydroxybenzoate (E 215), and Propyl para-hydroxybenzoate of sodium.
This medication may cause allergic reactions because it contains Yellow-orange S (E 110) and Red Cochineal A (E 124). They may provoke asthma, especially in patients allergic to acetylsalicylic acid.
This medication may cause allergic reactions (possibly delayed) because it contains sodium ethyl para-hydroxybenzoate (E 215) and propyl para-hydroxybenzoate of sodium.
This medication contains less than 1 mmol (23 mg) of sodium per capsule; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
In case of doubt, consult your doctor or pharmacist again.
Chronic venous insufficiency treatment:
The recommended dose is two 15 mg capsules twice a day (4 capsules per day) for 3 months.
Chronic venous ulcer:
It is recommended to start treatment with 60 mg per day via parenteral route (ampoules) for 15-20 days and continue with the oral formulation taking 2 capsules of 15 mg twice a day (4 capsules per day), which may be increased up to a maximum of 3 capsules of 15 mg twice a day (6 capsules per day). The recommended treatment duration is 2-3 months.
Symptomatic treatment of intermittent claudication in peripheral artery occlusive disease (stage II):
It is recommended to start treatment with 60 mg per day via parenteral route (ampoules) for 15-20 days and continue with the oral formulation taking 2 capsules of 15 mg twice a day (4 capsules per day), which may be increased up to a maximum of 3 capsules of 15 mg twice a day (6 capsules per day). The recommended treatment duration is 6 months.
Aterina capsules should be taken orally with liquid and separated from meals.
Use in children and adolescents
The safety and efficacy of Aterina in children and adolescents have not been established due to the absence of data.
Patients with liver problems
The use of Aterina capsules is not recommended in patients with liver disorders since there are no data on the safety and efficacy of the medication in these patients.
If you take more Aterina capsules than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you take more Aterina capsules than recommended, you may increase the risk of bleeding. If bleeding occurs, go to the nearest emergency service.
If you forgot to take Aterina capsules
In case of forgotten dose, take another as soon as possible, then follow the usual schedule. However, if there are only a few hours left until the next dose, do not take the forgotten dose and wait until the next one.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Aterina capsules
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
This medicine is usually well tolerated. The following side effects have been observed:
Frequent side effects(may affect up to 1 in 10 people):
Less frequent side effects(may affect up to 1 in 100 people):
Side effects of unknown frequency(cannot be estimated from available data):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly tothrough the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30 °C.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of ATERINA capsules
- 150 lipase units (ULS)
- 1,350 international anti-factor Xa units (UI anti Xa)
Appearance of the product and contents of the packaging
ATERINA capsules are presented in the form of soft gelatin capsules, orange in color, containing a white paste.
ATERINA capsules are available in packaging containing 60 soft capsules.
Holder of the marketing authorization and responsible for manufacturing
Holder:
Alfasigma España, S.L.
Avda. Diagonal, 490
08006 Barcelona. SPAIN
Responsible for manufacturing:
Alfasigma, S.p.A.
Via Enrico Fermi, 1
65020 Alanno, Pescara. ITALY
Last review date of this leaflet: June 2023
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.